The Pennsylvania denial segment captures a specific configuration: the member holds a fully-insured PID-licensed plan issued in Pennsylvania, with the dominant home-state BCBS affiliates (Highmark Blue Cross Blue Shield / Highmark Blue Shield for western PA, Capital BlueCross for central PA, Independence Blue Cross / IBC for the Philadelphia / southeastern PA region), the PA-specific integrated issuers (UPMC Health Plan in the Pittsburgh region, Geisinger Health Plan / Geisinger Quality Options in central / north-central PA), and the mainstream commercial carriers — Aetna, Cigna, Humana, UnitedHealthcare — operating PID-licensed fully-insured PPO/EPO products in PA. The denial reason will track the carrier's internal reason code (medical necessity, prior authorization, step therapy, formulary exclusion, out-of-network), but the appeal frameworks that attach are Pennsylvania-specific. The Pennsylvania Insurance Department (PID) regulates carriers under the Managed Care Plan Consumer Protection Act at 40 P.S. § 991d.117B et seq. — with § 117B.2 spelling out the carrier's standards for prompt investigation and payment of claims and the 21-day internal-review window keyed to the ABD, and § 117B.4 supplying the statutory external-review pathway (4-month filing window from the final internal ABD with the IRO list maintained by PID). The UR-agent standards under 31 Pa. Code § 89.44 govern utilization-review agent qualifications, clinical-criteria disclosure, and peer-reviewer escalation on utilization-review denials. The PID Consumer Services Bureau at 1-877-881-6388 and pid.pa.gov are the front door for Pennsylvania members.
PID-licensed carriers operating in Pennsylvania — Highmark (western PA), Capital BlueCross (central PA), Independence Blue Cross / IBC (southeastern PA), UPMC Health Plan, Geisinger Health Plan, Aetna, Cigna, Humana, UnitedHealthcare's fully-insured PA products — are subject to 40 P.S. § 991d.117B.2 et seq. and 40 P.S. § 117B.4, with the UR-agent standards under 31 Pa. Code Ch. 89 (and § 89.44 specifically) layering on top: a 21-day internal-review window from the ABD under § 117B.2, a 4-month statutory external review (IRO) window from the final internal ABD under § 117B.4 with the IRO list maintained by PID, and the UR-agent standards under 31 Pa. Code § 89.44 governing UR-agent qualifications, clinical-criteria disclosure, and peer-reviewer escalation. The PID complaint pathway under 40 P.S. § 117B and the § 117B.4 statutory external review channel run in parallel with the federal 4-month ACA external-review window at 45 C.F.R. § 147.136(d) for ACA marketplace plans operating in Pennsylvania, and the most protective of the two carries the day.
Self-funded ERISA plans — the typical larger-employer group plan where the employer pays the claims rather than buying insurance from a carrier — fall outside PID jurisdiction and outside 40 P.S. § 117B.4, and run through the federal ERISA § 503 claims-procedure rule at 29 C.F.R. § 2560.503-1, with the 4-month federal external-review channel at 29 C.F.R. § 2590.715-2719 for non-grandfathered plans and ERISA § 502(a) civil action at 29 U.S.C. § 1132(a)(1)(B) as the post-exhaustion remedy. Pennsylvania UR laws (31 Pa. Code Ch. 89; § 89.44 specifically) still apply to procedural aspects the federal rule does not preempt — UR-agent qualifications, clinical-criteria disclosure, peer-reviewer escalation — but the appeals timeline and the right-to-file-a-civil-action follow fully from 29 C.F.R. § 2560.503-1 and ERISA § 502(a). A well-built Pennsylvania appeal letter cites both: the controlling PA statute (40 P.S. § 117B.2 / 40 P.S. § 117B.4 for PID-licensed plans, plus 31 Pa. Code Ch. 89 / § 89.44 for the UR framework) or the federal preemption fallback (29 C.F.R. § 2560.503-1 for self-funded ERISA), and the right federal framework underneath.